Alnylam and Medtronic Advance Collaboration on Drug-Device Combinations with RNAi Therapeutics for CNS Diseases
Collaboration Focuses on RNAi Therapeutic Program for Huntington's Disease
01-Aug-2007 -
Medtronic, Inc. and Alnylam Pharmaceuticals, Inc. announced that the companies are advancing their collaboration initiated in February, 2005, following positive pre-clinical data generated under the initial joint technology development phase of the program.
Under the terms of the agreement, ...
Alnylam
diseases
Huntington's disease
+1